A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)
Clinical trial NCT05629585 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05629585
- Sponsor
- AstraZeneca
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2022-11-28
- Primary completion
- 2027-09-20
- Enrollment
- 1174
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.